Multiple G-Protein-dependent Pathways Mediate the Antisecretory Effects of Somatostatin and Clonidine in the HT29-19A Colonic Cell Line

G. Warhurst, L. A. Turnberg, N. B. Higgs, A. Tonge, J. Grundy, and K. E. Fogg

The Epithelial Membrane Research Centre and Department of Medicine, University of Manchester, Hope Hospital, Salford M6 8HD, United Kingdom

Abstract

Using the functionally differentiated colonic cell line, HT29-19A, we have examined sites at which inhibitory G-proteins mediate the antisecretory actions of somatostatin (SST) and the α_2 -adrenergic agonist, clonidine (CLON) at the epithelial level. Both agents caused a dose-dependent inhibition (EC_{50} : SST 35 nM; CLON 225 nM) of Cl^- secretion (assessed by changes in short circuit current) activated by cAMP-mediated agonists, PGE_2 and cholera toxin. Inhibition was accompanied by a reduction in intracellular cAMP accumulation and could be blocked by pretreatment with pertussis toxin at a concentration (200 ng/ml) which activated ADP-ribosylation of a 41-kD inhibitory G protein in HT29-19A membranes. Secretion stimulated by the permeant cAMP analogue, dibutyl cAMP, was also inhibited by SST and CLON (30–50%; $P < 0.005$), indicating additional inhibitory sites located distal to cAMP production. Both agents were effective inhibitors of secretion mediated through the Ca^{2+} signaling pathway. SST (1 μ M) and CLON (10 μ M) reduced the Isc response to the muscarinic agonist, carbachol, by 60–70%; inhibition was reversed in pertussis toxin-treated cells. These effects did not, however, involve inhibition of the carbachol-induced increase in cellular inositol 1,4,5-trisphosphate levels or the rise in cytosolic calcium, $[Ca]_i$. Inhibition by SST of secretion induced by phorbol 12,13 dibutyrate but not by the calcium agonist, thapsigargin, suggests that SST may act at a distal inhibitory site in the Ca^{2+} -dependent secretory process activated by protein kinase C. We conclude that SST and α_2 -adrenergic agonists can act directly on intestinal epithelial cells to exert a comprehensive inhibition of Cl^- secretion mediated through both cAMP and Ca^{2+} /protein kinase C signaling pathways. Inhibition is mediated via pertussis toxin-sensitive G-proteins at sites located both proximal and distal to the production of second messengers. (*J. Clin. Invest.* 1993; 92:603–611.) Key words: α_2 -adrenergic • cyclic adenosine monophosphate • inhibitory G-protein • intestinal epithelial cell • ion secretion • somatostatin

Introduction

Somatostatin (SST)¹ and alpha-2-adrenergic agonists (α_2 -ADR) are potent inhibitors of cAMP- and Ca^{2+} -mediated se-

cretion in the mammalian intestine (1–4). Both show promise as therapeutic agents in the treatment of secretory disorders (5). The cellular sites of action of these agonists and/or the nature of their molecular interaction with the secretory process, however, remain poorly defined. Evidence that tetrodotoxin and other neuronal blockers can inhibit the actions of SST and α_2 -ADR in some species suggests that the enteric nervous system may be an important site of action (2, 6). However, the identification of specific receptor sites for both types of agonist on enterocyte membranes (7, 8) implies a direct action mediated at the epithelial level.

In several systems SST and α_2 -ADR have been shown to mediate their cellular effects through the receptor activation of inhibitory G-proteins (G_i) coupled to the inhibition of adenylate cyclase (9, 10) and other membrane events including modulation of K^+ and Ca^{2+} channels (11, 12). Recent evidence suggests that G_i proteins are expressed in enterocytes and may mediate the receptor-activated inhibition of cAMP production (13) but we have little information on their role in attenuating secretory responses.

Recent studies using human colonic adenocarcinoma cell lines suggest that they may be useful models with which to address these questions. HT29 cells have been shown to express α_2 -ADR receptors coupled to the inhibition of adenylate cyclase (14, 15) and other mechanisms (16) though no attempt was made to investigate their linkage to ion transport processes. In the T84 cell line SST at high concentrations was reported to attenuate ion secretory responses (17) though the molecular mechanism of inhibition was not investigated.

In this study we have used the HT29-19A cell line, a differentiated subclone of HT29 that actively secretes Cl^- in response to neurohumoral agonists (18) to examine in greater detail the effects of SST and CLON in a pure epithelium. Our data suggest that both agents can inhibit cAMP- and Ca^{2+} /protein kinase C (PKC)-activated secretion, and that these effects are mediated by pertussis toxin (PT)-sensitive G-proteins directed at multiple sites along the secretory pathway located both proximal and distal to the generation of second messengers.

Methods

Cell culture. The HT29-19A colonic adenocarcinoma cell line was kindly supplied by Dr C. Laboisse, INSERM, Paris, and used between passages 38 and 52. Cells were grown in DME supplemented with 15 mM Hepes, 2 mM glutamine, 50 IU/ml penicillin, 50 μ g/ml streptomycin, and 10% fetal calf serum in a humidified atmosphere of 5% CO_2 /95% air at 37°C.

guanine-nucleotide-binding protein; IBMX, 3-isobutyl-1-methylxanthine; IP₃, inositol, 1,4,5-trisphosphate; Isc, short circuit current; PDB, 4 α -phorbol, 12,13-dibutyrate; PKC, protein kinase C; PT, pertussis toxin; RT, transepithelial resistance; SST, somatostatin; THAP, thapsigargin.

Address reprint requests to Dr. G. Warhurst, Department of Medicine, Hope Hospital Eccles Old Road, Salford M6 8HD, United Kingdom.

Received for publication 29 August 1991 and in revised form 1 March 1993.

1. Abbreviations used in this paper: α_2 -ADR, α_2 -adrenergic; CLON, clonidine; CT, cholera toxin; db-cAMP, dibutyl cAMP; G_i , inhibitory

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/93/08/0603/09 \$2.00

Volume 92, August 1993, 603–611

Monolayers of epithelial cells were formed on permeable filter supports. Cells were seeded at a density of $3 \times 10^5/\text{cm}^2$ onto a collagen-coated (rat tail; 2.5 mg/ml) filter (Millipore Corp., Bedford, MA) to which had been glued a silicone washer leaving a growing area of 1.13 cm^2 . After seeding, filters were initially floated on medium in petri dishes and were submerged after 18 h. Filters were used for transepithelial electrical studies 10–15 d after seeding. Under these conditions HT29-19A cells form a polarized epithelial monolayer (17). Cells grown on similar permeable supports were also used for measurements of intracellular cAMP (Millipore Corp.) or intracellular free calcium, $[\text{Ca}]_i$ (Nunc, Copenhagen, DK). Cellular levels of inositol 1,4,5-trisphosphate (IP_3) were measured in cells grown to confluency in 22-mm plastic dishes.

Measurements of transepithelial electrical responses. Changes in short circuit current (I_{sc}) were used as an indicator of electrogenic ion transport (18). Electrical parameters (I_{sc} and transepithelial resistance [R_T]) were measured using the Ussing chamber technique previously described (19). Cells were bathed at 37°C with a bicarbonate-buffered Ringer's solution that was gassed continuously with 5% $\text{CO}_2/95\% \text{O}_2$. Under these conditions HT29-19A cells exhibited a basal I_{sc} of $3.2 \pm 0.2 \mu\text{A}/\text{cm}^2$ and a mean R_T of $234 \pm 12.6 \Omega/\text{cm}^2$ ($n = 126$). The I_{sc} generated by these cells is assumed to be principally Cl^- based on the observations that I_{sc} stimulated by the cAMP agonist forskolin was (a) abolished in Cl^- -free media, (b) inhibited over 80% by serosal application of 100 μM bumetanide, and (c) unaffected by apical application of 1 mM amiloride. In addition, a recent study has also shown that forskolin stimulates apical ^{36}Cl efflux in this cell line (20).

Determination of cellular cAMP. Cell monolayers grown on Millipore filters were rinsed several times with a Hepes-buffered Ringer's solution (15 mM, pH 7.5) and incubated in the same buffer with agonists for various times at 37°C . Where indicated the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 0.25 mM) was included to minimize cAMP breakdown. Incubations were stopped by rapid washing in ice-cold Ringer's solution (< 5 s) and cellular cAMP extracted overnight at -70°C into ethanol/water (2:1). Extracts were dried under N_2 , reconstituted in Tris buffer (pH 7.5), and assayed for cAMP as previously described (19).

Determination of cellular IP_3 production. Cells were grown to confluency in 22-mm plastic dishes. After aspiration of the growth medium, cells were incubated in Hepes-Ringer's solution for 2 min at 37°C before addition of agonists. Incubations (0–5 min) were terminated by the addition of ice-cold perchloric acid (4% vol/vol) and kept on ice for 15 min. Samples of the perchloric acid extract were neutralized by addition of 5 M KOH and centrifuged at $12,000g$ for 5 min to remove KClO_4 precipitate. Aliquots of the supernatant were assayed for IP_3 using a binding protein isolated from bovine adrenal cortex as described by Palmer et al. (21). In some experiments, samples were assayed using a commercial IP_3 assay kit (Amersham International, Amersham, UK) that uses the same binding protein. Both assay systems gave similar values for IP_3 in HT29-19A extracts. Cross-reactivity of the binding protein with other inositol species including inositol 1,3,4-trisphosphate and inositol 1,3,4,5-tetrakisphosphate (IP_4) is 1% or less (21).

Measurement of intracellular calcium, $[\text{Ca}]_i$. $[\text{Ca}]_i$ was measured by dual excitation microfluorimetry using Fura-2 (22). Cells cultured for 5–7 d (80–90% confluent) on 10-mm polycarbonate tissue culture inserts (Nunc) were loaded in culture medium containing 10 μM Fura-2/AM for 45–60 min at 37°C . The monolayer was washed with Hepes-buffered Ringer's solution containing (in mM) 141 NaCl, 1.2 CaCl_2 , 1.2 MgCl_2 , 1.2 K_2HPO_4 , 1.8 KH_2PO_4 , 5 glucose, and 15 Hepes, pH 7.4. The tissue culture insert was mounted in a perfusion chamber on the stage of a Nikon Diaphot (Tokyo). Cells were perfused continuously at 2 ml/min on the basolateral surface with the same buffer at $22\text{--}24^\circ\text{C}$. Buffer bathing the apical surface was not changed during the experiment. Cells were excited alternately by light of 350 and 380 nm by means of a motor-driven filter changer and the emitted fluorescence at 510 nm (± 10 nm) from groups of four to six cells was monitored by photon counting (Newcastle Photometric Systems, Newcastle, UK). Fluorescence was corrected for background and autofluorescence be-

fore calculation of the 350/380 ratio, R . This routinely represented $< 20\%$ of the total signal. Where indicated, $[\text{Ca}]_i$ was also measured in cells grown on collagen-coated glass coverslips. In this case, background fluorescence was lower being routinely $< 8\%$ of the total signal.

$[\text{Ca}]_i$ was calculated with reference to a calibration curve relating $[\text{Ca}]_i$ (in nanomoles) to the 350/380 ratio. Values of R were measured in vitro using commercially available Ca^{2+} -EGTA buffer solutions yielding known free Ca^{2+} concentrations in the range 0–39.8 μM (Molecular Probes Inc., Eugene, OR) and containing 50 μM Fura-2. R values were measured in 20- μl droplets of each solution on a glass slide. Results are shown as representative tracings of at least four identical experiments.

ADP-ribosylation of HT29-19A membranes. PT-stimulated ADP-ribosylation of HT29-19A membranes was determined by a modification of the methods described by van den Berghe et al. (23) and Balda et al. (24). After incubation in the presence (200 ng/ml) or absence of PT for 18 h HT29-19A cells were washed, harvested, and homogenized in 25 mM Tris HCl, pH 7.5, containing 1 mM EDTA, 1 mM DTT, and 10 $\mu\text{g}/\text{ml}$ aprotinin. Membranes were prepared by centrifuging homogenates at $1,000g$ for 15 min followed by recentrifugation of the resulting supernatant at $20,000g$ for 20 min. Membranes were resuspended in the same buffer and the protein content was determined. ADP-ribosylation was performed by incubating 150 μg of membrane protein for 60 min at 32°C in a substrate mix (total volume 100 μl) containing 25 mM Tris-HCl, pH 8.0, 5 μM [^{32}P]NAD (5 $\mu\text{Ci}/\text{assay}$), 2 mM ATP, 0.1 mM GTP, 10 $\mu\text{g}/\text{ml}$ creatine phosphokinase, 20 mM creatine phosphate, 20 mM thymidine, 0.5 mM NADP^+ , 2.5 mM MgSO_4 , 5 mM EDTA, 1 mM EGTA, 20 mM β -glycerophosphate, 5 mM DTT, 5 $\mu\text{g}/\text{ml}$ leupeptin, 20 $\mu\text{g}/\text{ml}$ trypsin inhibitor, 0.025% saponin, and 2 μg of activated pertussis toxin (preactivated by incubation for 20 min at 37°C with 25 mM DTT). Control incubations in the absence of PT were also included. Reactions were terminated by addition of 400 μl of 20% trichloroacetic acid. Precipitated proteins were pelleted by centrifugation and the pellet washed once with 1 ml of diethyl ether. After allowing excess ether to evaporate the pellets were solubilized by boiling for 5 min in 0.066 M Tris-HCl, pH 7.0, containing 0.63 M mercaptoethanol, 4% SDS, 10% glycerol, and 0.01% bromophenol blue. Proteins were separated by SDS-PAGE on 10% gels according to the method of Laemmli (25). After fixing and staining gels were dried and exposed for autoradiography with Kodak X-OMAT AR film.

Statistical analysis. Results are expressed as mean $\pm$ SEM. All statistical comparisons were made using the unpaired Student's t test. Differences were considered significant when $P < 0.05$.

Materials. SST, CLON, PG E_2 , carbachol (CCh), yohimbine, cholera toxin (CT), phorbol 12,13 dibutyrate, and dibutyryl cAMP (db-cAMP) were from Sigma Chemical, Poole, UK. Thapsigargin (THAP), Fura-2, and Fura-2/AM were purchased from Calbiochem Corp., La Jolla, CA. Radiolabeled cAMP and IP_3 were from Amersham International, UK.

Results

SST and CLON inhibit cAMP-mediated secretion at sites proximal and distal to cAMP production. The cAMP agonist PGE_2 caused a rapid and sustained increase in I_{sc} across HT29-19A monolayers compatible with a stimulation of Cl^- secretion (Fig. 1 A). Application of SST (0.1 μM) to the basolateral bathing medium at the peak of the secretory response induced a rapid inhibition of I_{sc} by 60–70% within 3 min of addition. Inhibition was sustained for at least 60 min in the continued presence of SST. The adrenergic agonist CLON (10 μM) elicited a similar inhibitory response in PGE_2 -stimulated monolayers (Fig. 1 B) reducing I_{sc} by 85% within 2 min. Pretreatment with the α_2 -ADR receptor antagonist yohimbine (10 μM) reduced CLON-induced inhibition by over 90% (results not shown).

Figure 1. Effects of (A) SST and (B) CLON on the increase in Isc stimulated by 20 nM PGE₂. Studies were performed in (●) control cells and (○) cells pretreated with 200 ng/ml PT for 18 h. Values are from five to seven filters in each group. Dashed line shows typical response to 20 nM PGE₂ alone.

The inhibitory effects of SST on PGE₂-stimulated secretion were dose dependent with a threshold at 1 nM and a half-maximal response (EC₅₀) at 35 nM SST (Fig. 2 A). CLON-induced Isc inhibition was also dose-dependent although in this case the EC₅₀ was significantly higher at 225 nM (Fig. 2 B). In both cases the EC₅₀ values obtained in HT29-19A cells are similar to those reported for inhibition of fluid and electrolyte secretion in whole intestine (6, 26, 27).

The reversal of PGE₂-induced secretion by SST and CLON in HT29-19A monolayers was associated with a marked inhibition of cAMP production (Fig. 2). While for SST there was a close correlation between inhibition of Isc and cAMP (EC₅₀'s 35 and 31 nM, respectively) there appeared to be some dissociation of these parameters using CLON. The half-maximal concentration of CLON required to inhibit Isc (225 nM) was significantly higher ($P < 0.01$) than that for cAMP (70 nM) though the maximum level of inhibition was similar in both cases (82% vs. 79%). These results suggest that attenuation of cAMP production is a significant component of the antisecretory effects of SST and CLON in HT29-19A cells.

The role of G_i-proteins in the reversal of PGE₂-induced

secretion by SST and CLON was assessed by pretreating monolayers with PT, known to inactivate G_i in a variety of cell systems (28). Exposure of HT29-19A monolayers to 200 ng/ml PT for 18 h did not influence the secretory response to 20 nM PGE₂ (Isc [μ A/cm²]: untreated 27.2 ± 2.5 [$n = 10$]; PT treated 25.1 ± 1.6 [$n = 7$]) or the integrity of the cell monolayer (resistance [Ω /cm²]: untreated 269 ± 20.3 ; PT treated 311 ± 40.1 [$n = 14$]). However, PT treatment reduced by over 80% the inhibition of PGE₂-stimulated secretion by SST and CLON (Fig. 1) and effectively reversed their inhibitory effects on stimulated cAMP accumulation (Fig. 3).

To confirm that PT was acting on G_i-like proteins in this system we examined the ability of PT to ADP-ribosylate substrates in membranes from HT29-19A cells (Fig. 4). Incubation of membranes with activated PT (2 μ g) in the presence of [³²P]NAD selectively stimulated the labeling of a 41-kD protein. The intensity of other labeled bands was not increased by PT. In addition, incubation of intact cells with PT at concentrations used to inhibit the antisecretory actions of SST and CLON (200 ng/ml; 18 h) markedly reduced (by $\approx 80\%$ using densitometric analysis) the subsequent labeling of the 41-kD

Figure 2. Dose dependence of (a) SST- and (b) CLON-induced inhibition of PGE₂-stimulated ISc (□, ○) or cAMP accumulation (■, ●) measured in HT29-19A monolayers grown on permeable supports. Results are expressed as a percentage of inhibition of the response to 20 nM (Isc) or 100 nM (cAMP) PGE₂. These concentrations represent the approximate EC₅₀'s for PGE₂ stimulation of the two parameters. Results for ISc show maximal inhibition of ISc measured 3 min after addition and are adjusted for the spontaneous decrease in PGE₂-stimulated ISc over the same period ($5.4 \pm 1.5\%$). cAMP accumulation in response to PGE₂ was measured in cells

preincubated for 10 min with SST or CLON and compared to untreated cells. Data shown are mean $\pm$ SEM for four to seven filters at each point. Basal and PGE₂-stimulated cAMP levels were 3.2 ± 1.4 ($n = 6$) and 188.9 ± 22.0 ($n = 12$) pmol/mg protein, respectively.

Figure 3. Reversal of SST and CLON inhibition of PGE₂-stimulated cAMP accumulation by pertussis toxin. Cells were preincubated with SST (1 μ M), CLON (10 μ M), or Ringer's solution for 10 min before addition of 100 nM PGE₂ in the presence of 0.2 mM IBMX. Incubation was continued for 10 min. Where indicated cells were pretreated for 18 h with 200 ng/ml PT. ** $P < 0.01$ indicates inhibition of cAMP accumulation in response to SST or CLON compared to control. Results are mean $\pm$ SEM from five separate monolayers in each group.

band by PT in vitro (Fig. 4), confirming that PT can modify G-proteins in intact HT29-19A cells.

The ability of SST to inhibit secretion caused by CT, which permanently activates G_s (stimulatory guanine nucleotide-binding protein) resulting in a prolonged increase in cellular cAMP in intestinal cells, was also assessed. Table I shows that the rise in Isc stimulated by CT could be significantly inhibited by SST though inhibition was generally lower (45–50%) than that observed for the receptor agonist PGE₂. These effects were also accompanied by a reduction in the ability of CT to raise cAMP levels though, interestingly, the level of inhibition of cAMP accumulation was greater ($\approx 80\%$), suggesting that for CT there is a poorer correlation between Isc and cAMP than was observed for PGE₂. The effects of SST appear to be largely independent of CT concentration with both supramaximal (2 μ g/ml) and $\approx$ EC₅₀ (0.002 μ g/ml) doses exhibiting similar

Figure 4. ADP-ribosylation of 41-kD protein by pertussis toxin in HT29-19A membranes. Membranes prepared from control or PT-treated cells (200 ng/ml; 18 h) were incubated with [³²P]NAD for 60 min in the absence or presence of activated PT (20 μ g/ml) as described in Methods. After SDS-PAGE labeled proteins were detected by autoradiography.

levels of inhibition. Experiments with CT and CLON produced similar responses (results not shown).

Studies in intact intestine have shown significant reductions in basal ion transport in response to SST and CLON. In HT29-19A monolayers, however, these agonists had no effect on Isc in the unstimulated state (Isc [μ A/cm²]: basal 3.5 ± 0.7 ; +SST (1 μ M) 3.26 ± 1.3 ; +CLON (100 μ M) 2.9 ± 0.6 [$n = 5$]).

Increasing evidence suggests that some of the cellular effects of agonists that activate G_i-proteins may be mediated at sites distal to second messenger production (11). We, therefore, examined the effects of SST and CLON on the secretory response to the permeant cAMP analogue, db-cAMP. db-cAMP (200 μ M) caused a sustained activation of Isc in HT29-19A cells (Fig. 5). The addition of SST (1 μ M) at the peak of this response elicited a significant ($P < 0.005$) 30–35% inhibition of Isc—an effect that did not occur in PT-treated cells. CLON (10 μ M) produced a virtually identical response ($37.3 \pm 2.8\%$ inhibition of Isc measured 3 min after addition [$n = 7$]). Similar results were obtained using an alternative cAMP analogue, 8-bromo cAMP (results not shown).

Though the kinetics of inhibition were similar to those observed with the receptor-mediated agonist, PGE₂ comparison of the dose-response curves for SST inhibition of the two secretagogues (Fig. 6) showed interesting differences. First, unlike PGE₂, the maximal inhibition of db-cAMP-stimulated secretion that could be achieved with SST was significantly lower (40% vs. 85%), even though concentrations of PGE₂ and db-cAMP were chosen to produce similar increases in Isc (PGE₂ [20 nM] 26.3 ± 2.4 ; db-cAMP [200 μ M] 20.8 ± 2.1 μ A/cm²). Secondly, the maximum inhibition of secretion stimulated by 200 μ M db-cAMP could be achieved at a significantly lower concentration of SST (0.1 μ M). Despite these differences it was notable that the calculated EC₅₀'s for SST inhibition were virtually identical for each secretagogue (35 nM [PGE₂]; 30 nM [db-cAMP]). The effectiveness of SST as an inhibitor of db-cAMP-stimulated secretion appeared to be critically dependent on the concentration of db-cAMP used (Fig. 7). While SST was able to inhibit secretion induced by low concentrations (100 μ M) of db-cAMP by up to 60% at higher concentrations (> 400 μ M) inhibition was negligible.

These data suggest that the cAMP-activated secretory pathway in HT29-19A colonocytes has G_i-regulated sites located both proximal and distal to cAMP production which mediate the antisecretory actions of SST and CLON. Experiments were also conducted to examine the additivity of SST and CLON effects on db-cAMP-activated cells (Fig. 8). Separate addition of either agonist caused a 30–40% inhibition of Isc. However, when SST and CLON are added sequentially the inhibitory response to the second agonist is clearly attenuated producing a much less than additive response. Similar results were obtained when SST and CLON were added simultaneously. This may indicate that SST and α_2 -ADR receptors linked to the inhibition of secretion are coupled to a common pool of G_i-proteins.

Inhibition of secretion stimulated by Ca²⁺-mobilizing agonists. The Ca²⁺/PKC signaling system represents a second, discrete mechanism by which agonists can stimulate the Cl[−] secretory process in HT29-19A and other colonic cell lines (20, 29). We therefore investigated the ability of antisecretory agonists to modulate secretion stimulated by this route. We initially examined the effects of SST and CLON on the Isc response to the muscarinic agonist, CCh. In this cell line CCh (200 μ M) elicited a modest increase in Isc (6–7 μ A) compared to that seen with cAMP agonists. (Fig. 9 A). Pretreatment with

Table 1. Inhibition of CT-stimulated Isc and cAMP Accumulation by SST

	Isc			cAMP		
	Before SST	After SST	Percent inhibition by SST	Without SST	With SST	Percent inhibition by SST
	$\mu\text{A}/\text{cm}^2$			$\text{pmol}/\text{mg protein}$		
CT (2 $\mu\text{g}/\text{ml}$)	34.7 $\pm$ 5.4	19.1 $\pm$ 2.7*	45	1118 $\pm$ 87	233 $\pm$ 10*	79
CT (0.002 $\mu\text{g}/\text{ml}$)	14.5 $\pm$ 2.0	7.1 $\pm$ 1.7*	51	370 $\pm$ 19	79 $\pm$ 12*	78

Isc: Pre-SST values represent the peak Isc response to CT (normally 120–140 min after addition) recorded immediately before addition of 1 μM SST to the basolateral bathing medium. Post-SST values are Isc recorded 3 min after SST addition. In all cases basal Isc has been subtracted. cAMP: CT was added to HT29-19A monolayers bathed in Ringer's solution containing 0.2 mM IBMX; after 30 min 1 μM SST was added and the incubation was continued for a further 90 min. The filters were then washed rapidly in ice-cold Ringer's solution and cellular cAMP was extracted and assayed as described in Methods. Values are mean $\pm$ SEM for four or five monolayers in each group.

* $p < 0.05$; * $P < 0.01$ compared to monolayers without SST.

SST (1 μM) or CLON (10 μM) 5 min before CCh addition caused a 65–75% inhibition of the peak Isc response to 200 μM CCh. Inhibition could be reversed by pretreating cells with PT, suggesting that this effect is also mediated through PT-sensitive G-proteins (Fig. 9 B). Preliminary studies suggest that SST has similar effects on other receptor-mediated Ca^{2+} agonists including ATP and neurotensin (results not shown).

To investigate the possibility that inhibition is exerted at the level of the Ca^{2+} signaling pathway itself, we examined the effects of SST on CCh-induced IP_3 production and the subsequent mobilization of intracellular calcium, $[\text{Ca}]_i$. CCh stimulated a threefold increase in cellular IP_3 levels which peaked 8–10 s after agonist addition followed by a slow decline towards basal (Fig. 10). Pretreatment with 1 μM SST had no significant effect on CCh-induced IP_3 production. Similar results were obtained with CLON (data not shown). The CCh-induced in-

creases in IP_3 were associated with a rapid increase in $[\text{Ca}]_i$ measured in cells grown on permeable supports using the calcium sensitive indicator, Fura-2 (Fig. 11). After washout of the CCh cells were incubated for 5 min with SST before being stimulated again with CCh (Fig. 11, upper trace). SST did not influence either the peak rise in $[\text{Ca}]_i$ after readdition of CCh ($[\text{Ca}]_i$ above basal (nM): CCh 114 $\pm$ 12, CCh + SST (1 μM) 115 $\pm$ 6, CCh + CLON (10 μM) 128 $\pm$ 28 ($n = 4-7$) or the rate at which $[\text{Ca}]_i$ declined towards basal levels. Pretreatment with CLON (Fig. 11, lower trace) similarly had no significant effect on CCh-induced Ca^{2+} mobilization in these cells. Similar results were obtained using HT29-19A cells grown on collagen-coated glass coverslips though under these conditions there was a significantly larger response to CCh ($[\text{Ca}]_i$ above basal nM): CCh 204 $\pm$ 11, CCh + SST (1 μM) 224 $\pm$ 17; CCh + CLON (10 μM) 243 $\pm$ 15 ($n = 4-8$). SST and CLON had no effect on basal $[\text{Ca}]_i$ levels (results not shown). These observations suggest that SST and CLON again acting through G_i -coupled mecha-

Figure 5. Inhibition of db-cAMP (200 μM)-stimulated secretion by somatostatin (1 μM) in (●) untreated and (○) PT-treated (18 h; 200 ng/ml) monolayers. PT treatment had no significant effect on basal or db-cAMP-stimulated Isc compared to controls. Values are mean $\pm$ SEM for six experiments. The decrease in Isc after SST addition in non-PT-treated cells was highly significant ($P < 0.005$; paired t test) when compared with the Isc immediately before SST addition. No significant decrease in Isc occurred after SST addition in PT-treated cells. Dotted line shows typical response to 200 μM db-cAMP.

Figure 6. Dose-response relationship for SST-mediated inhibition of db-cAMP-induced increase in Isc. SST was added to monolayers 30 min after the addition of 200 μM db-cAMP. Results show the percent decrease in Isc measured 3 min after addition of SST (solid line). Isc in db-cAMP-stimulated cells that were not exposed to SST continued to rise slowly (0.5–1 μA) over this period. For comparison the dose-response curve for inhibition of PGE_2 -stimulated Isc is shown (dashed line). Values are mean $\pm$ SEM for four to six monolayers at each point.

Figure 7. SST inhibition of db-cAMP-activated Isc responses in HT29-19A cells: dependence on the concentration of db-cAMP. (●) Left abscissa: peak Isc response to db-cAMP (100–400 μM) in HT29-19A monolayers. (○) Right abscissa: percent inhibition by 1 μM SST of db-cAMP (100–400 μM)-stimulated Isc. Results show mean data from four to six monolayers in each group.

nisms inhibit secretion activated by Ca^{2+} -mobilizing agonists distal to both PI turnover and Ca^{2+} -mobilization. In an attempt to define further the site(s) of inhibition we examined (Fig. 12) the effects of SST on the rise in Isc caused by agents that either raise $[\text{Ca}]_i$ (THAP) or activate protein kinase C (4 α -phorbol, 12,13-dibutyrate; PDB) without stimulating significant phosphoinositol turnover (30). THAP (2 μM) caused only a minor increase in Isc ($1.5 \pm 0.1 \mu\text{A}/\text{cm}^2$ [$n = 9$]) across HT29-19A monolayers (Fig. 12) despite the fact that its effect on $[\text{Ca}]_i$ was similar to CCh (data not shown). SST (1 μM) added at the peak of this response caused no significant inhibi-

Figure 8. Nonadditivity of SST and CLON inhibition of db-cAMP-stimulated Isc in HT29-19A cells. Figure shows mean inhibition of Isc induced by SST or CLON when added separately or sequentially to HT29-19A monolayers treated with 200 μM db-cAMP. The inhibition in Isc was routinely recorded 4 min after addition. Dashed line indicates the expected inhibition if SST and CLON responses were additive. Rise in Isc above basal for db-cAMP (200 μM) was 15.7 ± 2.5 . Data are from five to eight monolayers in each group.

tion. In contrast, low concentrations of the PKC activator, PDB (20 nM), which has been shown to activate PKC in these cells (31) stimulated a larger increase in Isc ($5.1 \pm 0.4 \mu\text{A}/\text{cm}^2$ [$n = 7$]) similar to that produced by CCh though more prolonged (Fig. 12). In this case the addition of SST caused a rapid inhibition of Isc by $31.5 \pm 2.5\%$ ($n = 5$) within 2 min of addition to the basolateral surface. The simultaneous addition of THAP and PDB (Fig. 12) produced a greater than additive Isc response ($12.7 \pm 1.2 \mu\text{A}/\text{cm}^2$ [$n = 10$]). In the presence of both agonists SST again caused an inhibition of $29.0 \pm 6\%$ ($n = 5$).

These data indicate that, in this cell line, activation of PKC and not increases in $[\text{Ca}]_i$ may be the primary activator of Cl^- secretion though there is clearly a synergistic interaction between these two components of the Ca^{2+} pathway similar to that observed in the T84 cell line. The differential effect of SST would suggest that its ability to inhibit secretion induced by receptor-mediated Ca^{2+} agonists such as CCh may be due, at least in part, to the inhibition of a PKC-activated component of the Cl^- secretory process in HT29-19A cells.

Discussion

The present studies show that the peptide, SST and the α_2 -ADR agonist, CLON can act directly on the HT29-19A colonic cell line to inhibit the Isc, presumably due to Cl^- secretion, induced by both cAMP- and Ca^{2+} -dependent agonists. This effect mimics their antisecretory effects in the whole intestine. These actions appear to be mediated at multiple sites along the secretory pathway involving inhibition of cAMP generation but also at sites activated by cAMP and PKC activators which lie distal to second messenger production. Inhibition of Isc stimulated by all types of secretagogue could be effectively reversed by pretreating cells with PT at concentrations which cause the ADP-ribosylation of a 41-kD G_i -like protein in HT29-19A membranes.

Our studies suggest that the inhibition of cAMP generation is an important mechanism by which SST and CLON attenuate Cl^- secretion in these cells. G_i activation is commonly associated with an inhibition of adenylate cyclase and the PT-sensitive attenuation of cAMP accumulation by SST and CLON in HT29-19A cells is similar to that observed in other cell types. Other antisecretory agonists have been shown to limit cAMP production in intestinal cells including neuropeptide Y (32) and adenosine agonists acting through A_1 receptors (33). While the involvement of G_i was not tested in these studies it seems likely that the ability to lower intestinal cAMP levels through a G_i -linked mechanism may be a common feature of many agonists that act to limit secretion. In these studies there was a close relationship between the ability of SST to inhibit cAMP production and to reverse the Cl^- secretion induced by agonists which raise cellular cAMP, suggesting that this may be a primary site of action for this agent. In the case of CLON, however, there appeared to be some dissociation between inhibition of the two parameters. Several recent observations in other cells also suggest that the relationship between G_i -linked effects and the inhibition of cAMP may not be so clear-cut. In the shark rectal gland, adenosine agonists were able to inhibit completely forskolin-stimulated Cl^- secretion despite significantly elevated cAMP levels (33). Similarly, in the T84 cell line, secretion induced by high concentrations of PGE_2 could be maintained despite a marked inhibition of cAMP production (34). SST and α_2 -ADR also inhibited cAMP-mediated fluid secretion in intact mucosal preparations without signifi-

Figure 9. Effects of SST and CLON on CCh-stimulated Isc responses in HT29-19A cells. (A) Cells were pretreated for 5 min with (●) 1 μM SST, (□) 10 μM CLON, or (○) Ringer's solution (Arrow 1) before addition of 200 μM CCh (Arrow 2). SST and CLON elicited a significant inhibition ($P < 0.01$) of the CCh-induced Isc increase. Results are mean of six experiments in each group (B) Reversal of SST- and CLON-induced inhibition of CCh by PT. Results show effect of SST and CLON on CCh-induced Isc rise in cell monolayers pretreated with 200 ng/ml pertussis toxin for 18 h (open bars) or in untreated monolayers (hatched bars). Cells were exposed to SST or CLON 5 min before CCh and data are expressed as a percentage of the normal response to CCh. Results are mean ± SEM from five monolayers in each group. ** $P < 0.005$.

cant changes in tissue cAMP levels (27, 35, 36) though in this case the possibility remains that measurements of whole mucosal cAMP may mask changes in specific epithelial "pools" of cAMP.

There is considerable evidence from the present study, however, that while the ability to lower epithelial cAMP levels is a characteristic property of antisecretory agents, they also interact with the secretory pathway at additional G-protein-linked sites which bypass the adenylate cyclase system.

First, SST and CLON were able to partially inhibit secretion induced by the permeant cAMP analogues, db-cAMP and 8-bromo cAMP—an effect that was also blocked by PT.

Secondly, both agonists were also effective inhibitors of secretion induced by the receptor-mediated Ca^{2+} -mobilizing ago-

Figure 10. Effect of SST (1 μM) on CCh-induced increase in IP_3 levels in HT29-19A cells. Cells grown to confluency in 22-mm plastic dishes were washed free of medium and suspended in HEPES-Ringer's solution before addition of (■) 1 μM SST or (□) solvent. After 5 min medium was aspirated and replaced by fresh Ringer's solution con-

taining either (□) 100 μM CCh or (■) 100 μM CCh + 1 μM SST. After incubation for 0–120 s reactions were stopped by rapid aspiration and addition of ice-cold perchloric acid. Cellular IP_3 was extracted and assayed as described in Methods. Results are mean ± SEM from five determinations.

Figure 11. Effects of SST (upper trace) and CLON (lower trace) on CCh-induced increases in $[\text{Ca}^{2+}]_i$ in HT29-19A cells. $[\text{Ca}^{2+}]_i$ was measured in Fura-2-loaded cells grown on permeable supports as described in Methods. Results show representative tracings from four experiments in each group. The axis on the right shows the 350/380-nm ratio which was used to calculate the $[\text{Ca}^{2+}]_i$ values (in nM) shown on the left axis. Mean data for the peak rise in $[\text{Ca}^{2+}]_i$ induced by CCh in the presence and absence of SST/CLON are given in the text.

Figure 12. SST inhibition of I_{sc} activated by THAP and PDB in HT29-19A monolayers. 2 μ M THAP (Δ , $\blacktriangle$), 20 nM PDB ($\circ$, $\bullet$), or a combination of both ($\square$, $\blacksquare$) was added to cell monolayers as indicated. At the peak of the I_{sc} response either 1 μ M SST ($\blacktriangle$, $\bullet$, $\blacksquare$) or solvent control (Δ , $\circ$, $\square$) were added indicated by the arrow. Results are representative data from one of at least four similar experiments for each condition.

nist, CCh reducing its effects by 60–70%. This action, again reversed by PT, occurred without any apparent inhibition of either IP_3 production or increases in cytosolic free calcium, $[Ca]_i$. Other studies with somatostatin in intestinal cells have also implied a site of action distal to the rise in $[Ca]_i$ though in neither case was the involvement of G-proteins investigated. A preliminary study in chicken enterocytes showed that epinephrine had no effect on agonist-stimulated increases in $[Ca]_i$ despite being a potent inhibitor of Ca^{2+} dependent secretion in the intact mucosa (37) while in T84 cells high concentrations of SST (10 μ M) were shown to inhibit Cl^- secretion induced by a calcium ionophore (17). In some tissues there is evidence that SST acting through G_i can modulate some aspects of the Ca^{2+} signaling pathway including inhibition of Ca^{2+} channel opening (38) but we could find no evidence for this occurring in HT29-19A cells. The results of experiments using selective activators of the Ca^{2+} and PKC arms of the signaling pathway provide some indication that SST may act distally to inhibit a PKC-activated component of Cl^- secretion. Increasing $[Ca]_i$ alone with THAP appears to be a poor activator of Cl^- secretion generating minor increases in I_{sc} in these cells. However, PDB, an activator of PKC produced significant increases in I_{sc} particularly when added simultaneously with THAP. Similar effects of PKC-activators have been reported in a recent study of HT29-19A cells by Bajnath et al. (31, 39), suggesting that PKC-dependent processes play a significant role in activating the Cl^- secretory process in these cells. The ability of SST to induce a rapid, although partial, inhibition of PDB-induced secretion while having no significant effect on that induced by THAP alone suggests that SST acts to inhibit Ca^{2+} /PKC-dependent secretion at a PKC-activated site in these cells. The ability of SST to inhibit the actions of PDB coupled with its lack of effect on IP_3 (and therefore by inference associated diacylglycerol production) suggests a site of action distal to the activation of PKC itself. The possibility that SST may influ-

ence diacylglycerol production generated from other sources such as the breakdown of phosphatidylcholine must also be considered (40).

The characteristics of inhibition observed using nonreceptor agonists to stimulate secretion were somewhat different from those seen with receptor mediated agonists. The secretion induced by nonreceptor agonists generally appeared to be more difficult to inhibit with both db-cAMP and PDB (25–50%) showing a lesser degree of inhibition than either PGE_2 or CCh (60–80%). In addition, with db-cAMP, the maximum level of inhibition appeared to be critically dependent on the extent to which the Cl^- secretory process had been stimulated. Thus, at concentrations of db-cAMP > 400 μ M (I_{sc} rise 40 μ A) inhibition was negligible while the same concentration of SST caused a 50% reduction in secretion induced by 100 μ M db-cAMP (I_{sc} rise 10 μ A). One explanation for this may be that G_i -like proteins regulate a distal site or sites which become increasingly rate limiting at suboptimal stimulation of the secretory pathway. Similarly, agonists that bypass the normal second messenger synthesis/degradation processes may be inherently more difficult to inhibit. The relative sensitivity of receptor-mediated agonists to SST and CLON would presumably result from inhibition being mediated at both proximal and distal sites.

The nature of the distal inhibitory site in HT29-19A cells remains uncertain. Both cAMP agonists and PKC activators have been shown to stimulate apical Cl^- secretion in these cells but cause relatively small increases in basolateral K^+ movement (20, 39). Raising $[Ca]_i$ alone appears to have the opposite effect-stimulating large increases in basolateral K^+ efflux with much smaller effects on apical Cl^- secretion (20; and manuscript in preparation). Similar observations have been made in the T84 cell line where increases in $[Ca]_i$ were also shown to have a greater effect on basolateral K^+ permeability than on apical Cl^- channels (41). In preliminary studies we have found that SST has no influence on CCh-stimulated ^{86}Rb efflux in HT29-19A despite significantly inhibiting the CCh-induced rise in I_{sc} (G. Warhurst, unpublished observations). It is interesting to speculate from the differential effect of SST on these components that at least one site lies in close proximity to the apical Cl^- channel. Receptors linked through G_i have been shown to couple to ion conductances in a variety of cell types (11, 38) and there is growing evidence that G-proteins play a role in regulating ion channels in intestinal epithelial cells. Recent studies have identified a G-protein activated Cl^- channel in the HT29-19A cell line (42) while G-proteins have also been implicated in the negative modulation of K^+ conductances in guinea pig enterocytes (43) an action that could also result in the attenuation of transepithelial ion secretion.

Several G-proteins acting as substrates for PT have been identified including at least three subtypes of G_i and it has been suggested that these may couple to specific receptors or that different subtypes may allow the same receptor to link to different effector systems (44). A recent study has shown that enterocyte membranes express the PT-sensitive G-protein subtypes, α_{i-2} and α_{i-3} (23) though their involvement in regulating specific epithelial functions remains to be determined. Identification of the specific G-protein subtypes involved in coupling SST and CLON receptors to proximal and distal inhibitory sites in the secretory process and their location in apical or basolateral membrane domains will, clearly, be an important progression of the observations made in the present study.

In the whole intestine there are likely to be multiple cellular sites at which antisecretory agonists may act including neuro-

nal elements, endocrine cells, immune cells, and the epithelium itself. Action at all these sites may contribute, directly or indirectly, to the overall inhibition of secretion. However, the observations in this study that SST and CLON, acting through PT-sensitive G-proteins, can inhibit a broad range of secretagogues in a functional epithelial model system suggests that the epithelium is likely to be an important site of action for antisecretory agonists.

Acknowledgments

The authors thank Dr C. L. Laboisse, INSERM, Paris, for providing the HT29-19A clonal cell line.

This work was supported by Sir Jules Thorne Charitable Trust and the Wellcome Trust, UK.

References

1. Dharmasathaporn, K., R. S. Sherwin, and J. W. Dobbins. 1980. Somatostatin inhibits fluid secretion in the rat jejunum. *Gastroenterology*. 78:813-820.
2. Keast, J. R., J. B. Furness, and M. Costa. 1986. Effects of noradrenaline and somatostatin on basal and stimulated mucosal ion transport in the guinea pig small intestine. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 333:393-399.
3. Knobloch, S. F., M. Diener, and W. Rummel. 1989. Antisecretory effects of somatostatin and vasopressin in the rat colon descendens in vitro. *Regul. Pept.* 25:75-85.
4. Pamukcu, R., and E. B. Chang. 1990. Alpha-2-adrenergic agonists as antidiarrheal agents: a review of physiological and cellular mechanisms. In *Textbook of Secretory Diarrhea*. E. Lebenthal and M. Duffey, editors. Raven Press, New York. 383-408.
5. Donowitz, M., S. Levine, and A. Watson. 1990. New drug treatments for diarrhoea. *J. Intern. Med.* 228:155-163.
6. Brown, D. R., M. F. Overend, and B. G. Treder. 1990. Neurohormonal regulation of ion transport in the porcine distal jejunum: actions of somatostatin-14 and its natural and synthetic homologs. *J. Pharmacol. Exp. Ther.* 252:126-134.
7. Weber, M., T. Cole, and J. M. Conlon. 1985. Specific binding and degradation of somatostatin by membrane vesicles from pig gut. *Am. J. Physiol.* 250:G679-685.
8. Chang, E. B., M. Field, and R. J. Miller. 1983. Enterocyte alpha-2-adrenergic receptors: yohimbine and *p*-aminoclonidine binding relative to ion transport. *Am. J. Physiol.* 244:G76-82.
9. Limbird, L. E., and J. D. Sweatt. 1985. Alpha-2-adrenergic receptors: apparent interaction with multiple effector systems. In *The Receptors*. Volume 2. P. M. Conn, editor. Academic Press, Inc., New York. 281-307.
10. Toro, M. J., L. Birnbaumer, M. C. Redon, and E. Montoya. 1988. Mechanism of action of somatostatin. *Horm. Res.* 29:59-64.
11. Limbird, L. E. 1988. Receptors linked to inhibition of adenylate cyclase: additional signalling mechanisms. *FASEB J.* 2:2686-2695.
12. Inoue, L., and M. Yoshi. 1992. Modulation of ion channels by somatostatin and acetylcholine. *Prog. Neurobiol.* 38:203-230.
13. van den Berghe, N., N. J. Nieuwkoop, A. B. Vaandrager, and H. R. de Jonge. 1991. Asymmetrical distribution of G-proteins among the apical and basolateral membranes of rat enterocytes. *Biochem. J.* 278:565-571.
14. Turner, J. T., C. Ray-Premger, and D. B. Bylund. 1985. Alpha-2-adrenergic receptors in the human cell line, HT29: characterization with full agonist radioligand [³H]UK-14, 304 and inhibition of adenylate cyclase. *Mol. Pharmacol.* 28:422-430.
15. Bouscarel, B., C. Cortinovis, C. Carpenne, J. C. Murat, and H. Paris. 1985. Alpha-2-adrenoreceptors in the HT29 human colon adenocarcinoma cell line: characterisation with [³H]clonidine: effects on cyclic AMP accumulation. *Eur. J. Pharmacol.* 107:223-231.
16. Jones, S. B., and D. B. Bylund. 1988. Characterisation and possible mechanisms of alpha-2-adrenergic receptor-mediated sensitisation of forskolin-stimulated cyclic AMP production in HT29 cells. *J. Biol. Chem.* 263:14236-14244.
17. Dharmasathaporn, K., K. G. Mandel, J. A. McRoberts, L. D. Tisdale, and H. Masui. 1984. A human colonic tumor cell line that maintains vectorial electrolyte transport. *Am. J. Physiol.* 246:G204-208.
18. Augeron C., J. J. Maoret, C. L. Laboisse, and E. Grasset. 1986. Permanently differentiated cell clones isolated from the human colonic adenocarcinoma cell line HT29: possible models for the study of ion transport and mucus production. In *Ion Gradient Coupled Transport*. INSERM Symp. 26:363-366.
19. Warhurst, G., N. B. Higgs, M. Lees, A. Tonge, and L. A. Turnberg. 1988. C-kinase modulation of cAMP production and electrical responses to prostaglandin E₂ in a colonic epithelial cell line. *Am. J. Physiol.* 255:G27-32.
20. Vaandrager, A. B., Bajnath, R., Groot, J. A., Bot, A. G. M. and H. R. de Jonge. 1991. Ca²⁺ and cAMP activate different chloride efflux pathways in HT-29.c19A colonic epithelial cell line. *Am. J. Physiol.* 261:G958-G965.
21. Palmer, S., K. T. Hughes, D. Y. Lee, and M. J. O. Wakelam. 1989. Development of a novel, Ins(1,4,5)P₃-specific binding assay. Its use to determine the intracellular concentration of Ins(1,4,5)P₃ in unstimulated and vasopressin-stimulated rat hepatocytes. *Cell. Signalling*. 1:147-156.
22. Grynkiewicz, G., M. Poenie, and R. Y. Tsien. 1985. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. *J. Biol. Chem.* 260:3440-3450.
23. van den Berghe, N., Nieukoop, N. J., Vaandrager, A. B., and H. R. de Jonge. 1991. Asymmetrical distribution of G-proteins among the apical and basolateral membranes of rat enterocytes. *Biochem. J.* 278:565-571.
24. Balda, M. S., Gonzalez-Mariscal, L., Contreras, R. G., Macias-Silva, M., Torres-Marquez, M. E., Garcia-Sainz and M. Cerejido. 1991. Assembly and sealing of tight junctions: possible participation of G-proteins, phospholipase C, protein kinase C and calmodulin. *J. Membr. Biol.* 122:193-202.
25. Laemmli, U. K. 1970. Cleavage of structural proteins during assembly of the head of bacteriophage T4. *Nature (Lond.)*. 227:680-685.
26. Chang, E. B., M. Field, and R. J. Miller. 1982. Alpha-2-adrenergic receptor regulation of ion transport in rabbit ileum. *Am. J. Physiol.* 242:G237-G242.
27. Guandalini, S., J. F. Kachur, P. L. Smith, R. J. Miller and M. Field. 1980. In vitro effects of somatostatin on ion transport in rabbit intestine. *Am. J. Physiol.* 238:G67-74.
28. Katada, T., and M. Ui. 1982. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. *Proc. Natl. Acad. Sci. USA*. 79:3129-3133.
29. Dharmasathaporn, K., J. Cohn, and G. Beuerlein. 1989. Multiple calcium-mediated effector mechanisms regulate chloride secretory responses in T84 cells. *Am. J. Physiol.* 256:C1224-1230.
30. Thastrup, O. 1990. Role of Ca²⁺-ATPase in regulation of cellular Ca²⁺ signalling as studied with the selective microsomal Ca²⁺-ATPase inhibitor, thapsigargin. *Agents Actions*. 29:8-15.
31. van den Berghe, N., A. B. Vaandrager, A. G. M. Bot, P. J. Parker, and H. R. de Jonge. 1992. Dual role for protein kinase C α as a regulator of ion secretion in the HT29cl.19A human colonic cell line. *Biochem. J.* 285:673-679.
32. Voisin, T., C. Rouyer-Fessard, and M. Laburthe. 1990. Distribution of common peptide YY-neuropeptide Y receptor along rat intestinal villus-crypt axis. *Am. J. Physiol.* 258:G753-759.
33. Kelley, G. G., E. M. Poeschla, H. Barron, and J. N. Forrest, Jr. 1990. A₁ adenosine receptors inhibit chloride transport in the shark rectal gland: dissociation of inhibition and cyclic AMP. *J. Clin. Invest.* 85:1629-1636.
34. Warhurst, G., N. B. Higgs, A. Tonge, and L. A. Turnberg. 1991. Stimulatory and inhibitory actions of carbachol on chloride secretory responses in human colonic cell line, T84. *Am. J. Physiol.* 261:G220-G228.
35. Donowitz, M., S. Cusolito, L. Battisti, R. Fogel, and G. W. G. Sharp. 1982. Dopamine stimulation of active Na and Cl absorption in rabbit ileum: interaction with alpha-2-adrenergic and specific dopamine receptors. *J. Clin. Invest.* 69:1008-1016.
36. Nakai, T., T. Nakadate, S. Yamanoto, and R. Kato. 1982. Alpha-2-adrenergic inhibition of intestinal secretion induced by prostaglandin E₁, vasoactive intestinal peptide and dibutyryl-cAMP in rat jejunum. *J. Pharmacol. Exp. Ther.* 220:637-641.
37. Chang, E. B., A. J. Gill, N. S. Wang, and M. Field. 1984. Alpha-2-adrenergic inhibition of Ca-dependent intestinal secretion. *Gastroenterology*. 85:1044. (Abstr.)
38. Rosenthal, W., J. Hescheler, R. Eckert, S. Offermanns, A. Schmidt, K. D. Hinsch, K. Spicher, W. Trautwein, and G. Schultz. 1990. Pertussis toxin-sensitive G-proteins: participation in the modulation of voltage-dependent Ca²⁺ channels by hormones and neurotransmitters. *Adv. Second Messenger Phosphoprotein Res.* 24:89-95.
39. Bajnath, R. B., M. H. van Hoeve, H. R. de Jonge, and J. A. Groot. 1992. Regulation of apical Cl⁻ conductance and basolateral K⁺ conductances by phorbol esters in HT29cl.19A cells. *Am. J. Physiol.* 263:C759-C766.
40. Exton, J. H. 1990. Signalling through phosphatidylcholine breakdown. *J. Biol. Chem.* 265:1-4.
41. Cartwright, C. A., J. A. McRoberts, K. G. Mandel, and K. Dharmasathaporn. 1985. Synergistic action of cyclic adenosine monophosphate- and calcium-mediated chloride secretion in a colonic epithelial cell line. *J. Clin. Invest.* 76:1837-1842.
42. Tilly, B. C., M. Kansen, P. J. M. van Gageldonk, N. van den Berghe, H. Galjaard, J. Bijman, and H. R. de Jonge. 1991. G-proteins mediate intestinal chloride channel activation. *J. Biol. Chem.* 266:2036-2040.
43. Fargon, F., P. A. McNaughton, and F. V. Sepulveda. 1990. Possible involvement of GTP-binding proteins in the deactivation of an inwardly rectifying K⁺ current in enterocytes isolated from guinea-pig intestine. *Pflügers Arch. Eur. J. Physiol.* 417:240-242.
44. Milligan, G., I. Mullaney, and F. R. McKenzie. 1990. Specificity of interactions of receptors and effectors with GTP-binding proteins in native membranes. In *G-proteins and Signal Transduction*. *Biochem. Soc. Symp.* 56:21-35.